Elicio Therapeutics ELTX Income Statement (2020-2026)

NASDAQ ELTX
$3.08 -0.06 (-1.76%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
1.46M25.94M1.65M0.65M
Cost of Revenue (Quarter)
0.43M
Gross Profit (Quarter)
1.46M25.51M
Operating items
Research & Development (Quarter)
13.29M6.67M11.67M5.04M4.59M4.29M5.48M4.94M7.26M6.16M7.56M8.18M7.21M10.71M7.78M7.01M5.04M5.08M6.76M6.81M
Selling, General & Administrative (Quarter)
3.93M4.21M4.47M1.19M1.18M1.67M2.32M2.83M3.51M3.23M2.68M2.74M3.14M2.77M2.96M3.08M3.01M3.76M3.85M3.62M
Restructuring Costs (Quarter)
2.80M3.15M
Other Operating Expenses (Quarter)
-0.10M0.10M0.00M
Operating Expenses (Quarter)
17.22M11.31M16.13M6.23M5.77M5.96M7.80M7.78M10.77M9.39M10.24M10.92M10.34M13.48M10.74M10.09M8.04M8.84M10.60M10.43M
Operating Income (Quarter)
-15.76M14.63M-14.48M-6.23M-5.77M-5.96M-7.80M-7.78M-10.77M-9.39M-10.24M-10.92M-10.34M-13.48M-10.74M-10.09M-8.04M-8.84M-10.60M-10.43M
EBIT (Quarter)
-15.76M14.63M-14.48M-6.23M-5.77M-5.96M-7.80M-7.78M-10.77M-9.39M-10.24M-10.92M-10.34M-13.48M-10.74M-10.09M-8.04M-8.84M-10.60M-10.43M
Non-operating items
Interest & Investment Income (Quarter)
0.04M0.25M0.14M0.18M0.21M0.17M0.20M0.16M0.14M
Other Non Operating Income (Quarter)
-0.20M1.18M0.11M-0.11M0.60M-0.03M0.47M0.15M-0.01M-0.00M0.01M0.01M0.00M
Non Operating Income (Quarter)
0.05M0.26M0.24M-1.07M-1.43M-4.49M0.01M0.22M0.11M0.44M-1.59M3.69M-8.49M-0.53M-0.47M-0.47M-2.04M1.12M-1.22M2.21M
Net income details
EBT (Quarter)
-41.04M14.32M-14.81M-7.34M-10.23M-6.05M-8.15M-11.25M-19.72M-9.77M-10.62M-18.84M-10.30M-12.84M-10.86M-16.64M-18.37M-9.18M-22.00M-15.64M
Profit After Tax (Quarter)
-15.56M14.86M-7.06M-7.30M-7.20M-6.65M-8.03M-7.56M-10.68M-9.15M-11.83M-7.23M-18.84M-14.00M-11.18M-10.56M-10.04M-7.81M-11.82M-8.22M
Equity Income (Quarter)
0.02M-0.14M0.01M0.13M0.01M
Income from Continuing Operations (Quarter)
-41.04M14.32M-14.81M-7.34M-10.23M-6.05M-8.15M-11.25M-19.72M-9.77M-10.62M-18.84M-10.30M-12.84M-10.86M-16.64M-18.37M-9.18M-22.00M-15.64M
Consolidated Net Income (Quarter)
-41.04M14.32M-14.81M-7.34M-10.23M-6.05M-8.15M-11.25M-19.72M-9.77M-10.62M-18.84M-10.30M-12.84M-10.86M-16.64M-18.37M-9.18M-22.00M-15.64M
Income towards Parent Company (Quarter)
-41.04M14.32M-14.81M-7.34M-10.23M-6.05M-8.15M-11.25M-19.72M-9.77M-10.62M-18.84M-10.30M-12.84M-10.86M-16.64M-18.37M-9.18M-22.00M-15.64M
Net Income towards Common Stockholders (Quarter)
-41.04M14.32M-14.81M-7.34M-10.23M-6.05M-8.15M-11.25M-19.72M-9.77M-10.62M-18.84M-10.30M-12.84M-10.86M-16.64M-18.37M-9.18M-22.00M-15.64M
Additional items
EPS (Basic) (Quarter)
-13.765.07-4.94-2.45-3.40-2.01-2.71-3.63-2.35-1.93-1.03-1.67-0.76-1.05-0.84-1.04-1.10-0.60-1.21-0.81
EPS (Diluted) (Quarter)
-13.765.07-4.94-2.45-3.40-2.01-2.71-3.63-2.35-1.93-1.03-1.67-0.76-1.05-0.84-1.04-1.10-0.60-1.21-0.81
Shares Outstanding (Quarter)
2.98M2.82M3.00M3.00M3.01M3.00M3.01M3.10M8.38M5.06M10.27M11.28M13.58M12.20M12.95M16.06M16.69M15.31M18.21M19.24M
Shares Outstanding (Diluted) (Quarter)
2.98M2.82M3.00M3.00M3.01M3.00M3.01M3.10M8.38M5.06M10.27M11.28M13.58M12.20M12.95M16.06M16.69M15.31M18.21M19.24M
Shares Outstanding (Entity) (Quarter)
3.04M3.00M3.00M3.01M3.01M3.01M3.01M3.10M8.38M5.06M10.23M10.27M13.58M11.04M12.95M16.28M17.27M17.81M18.65M21.90M
EBITDA (Quarter)
-15.76M14.63M-14.48M-6.23M-5.77M-5.96M-7.80M-7.78M-10.77M-9.39M-10.24M-10.92M-10.34M-13.48M-10.74M-10.09M-8.04M-8.84M-10.60M-10.43M
Interest Expenses (Quarter)
25.28M0.32M0.32M1.10M4.46M0.09M0.34M3.51M9.19M0.38M0.38M8.05M0.14M-0.64M0.33M6.71M10.53M0.34M11.55M5.35M